From today's announcement: Dr John Wilkinson remains as Chief Scientific Officer but will have a focus on supporting the Veyonda clinical program. This is a required key focus with the program facing a significant increase in clinical activity in 2020 including the prospect of Veyonda entering a registration study in 2020.
24-week data for the 1200 mg expansion cohort in DARRT-1 is due in November, just before the AGM. If the data are good, as they should be given the excellent responses after 12 weeks, it looks like Noxopharm intends to jump from Phase I direct into a registration trial.
- Forums
- ASX - By Stock
- NOX
- Interesting
Interesting
Featured News
IGO
IGO kicks off earn-in copper drilling on-site Encounter's Yeneena play as it adopts new identity
MND
Monadelphous inks $200M contract with Woodside to help build Pluto LNG – but will it make Scarborough cheaper?
Add NOX (ASX) to my watchlist
|
|||||
Last
7.2¢ |
Change
0.000(0.00%) |
Mkt cap ! $21.04M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 14000 | 6.8¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
7.2¢ | 8810 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 14000 | 0.068 |
1 | 1672 | 0.066 |
1 | 15000 | 0.065 |
1 | 79000 | 0.063 |
1 | 100000 | 0.062 |
Price($) | Vol. | No. |
---|---|---|
0.072 | 8810 | 1 |
0.074 | 50000 | 1 |
0.076 | 4999 | 1 |
0.079 | 12000 | 1 |
0.080 | 100000 | 1 |
Last trade - 07.00am 29/07/2024 (20 minute delay) ? |
Featured News
NOX (ASX) Chart |
Day chart unavailable